CompBrief BY VELARION

Companies VBI Vaccines Inc/BC

VBI Vaccines Inc/BC CEO salary & total pay, FY2023: $894K

VBI Vaccines Inc/BC (VBIVQ) CEO salary, fiscal 2023: Jeffrey Baxter was paid a salary of $697,928 and $893,546 in total compensation. Free brief. Every figure links to the company’s own filing.

VBI Vaccines Inc/BC no longer files a proxy statement; its last pay data is FY2023.

All products and prices

Jeffrey Baxter's complete compensation dossier

A PDF and a CSV sent to your email: Jeffrey Baxter's pay in every fiscal year VBI Vaccines Inc/BC reported it, line by line, with Jeffrey Baxter's equity grants and VBI Vaccines Inc/BC's disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$893,546CEO Jeffrey Baxter · source
Say-on-pay support90.77%Latest vote · source
CEO vs. named peers1st pct.Of 22 peer CEOs

CEO pay, last three years

  • $1,830,436FY2022
  • $893,546FY2023

CEO total pay was $893,546 in fiscal 2023, down from $1,830,436 in fiscal 2022.

FY2023: salary $697,928 · bonus $0 · stock awards $0 · option awards $121,736

Executives and directors

Frequently asked questions

Who was the highest-paid executive at VBI Vaccines Inc/BC in fiscal 2023?
As disclosed, Jeffrey Baxter (President, Chief Executive Officer) was the highest-paid executive at VBI Vaccines Inc/BC in fiscal 2023, with total compensation of $893,546.
How does VBI Vaccines Inc/BC's chief executive pay compare to its disclosed peer group?
As disclosed, Jeffrey Baxter's total compensation ranked at the 1st percentile of VBI Vaccines Inc/BC's disclosed peer group.
How did shareholders vote on VBI Vaccines Inc/BC's executive compensation?
As disclosed, 90.77% of shareholders supported VBI Vaccines Inc/BC's executive compensation in the latest say-on-pay vote.
How much does VBI Vaccines Inc/BC spend in total on board compensation for fiscal 2023?
As disclosed, VBI Vaccines Inc/BC reported total board compensation of $357,500 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jeffrey Baxter$697,928$0$0$121,736$0$0$73,883$893,546
President, Chief Executive Officer
David Anderson458,3500091,3050014,900564,555
Chief Scientific Officer
Francisco Diaz-Mitoma457,9160091,305000549,221
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Jeffrey Baxter$893,546$1,830,436—↓ −936,890
David Anderson564,555995,438—↓ −430,883
Francisco Diaz-Mitoma549,2211,005,705—↓ −456,484

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

VBI's compensation program aims to attract, motivate, and retain skilled individuals by aligning executive interests with stakeholders through a mix of base salary, annual cash bonuses, spot recognition awards, and equity grants that reward short-term and long-term performance.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
David AndersonOption16,14652094.5—
David AndersonOption7,9225,41145.9—
David AndersonOption—2,50017.25—
David AndersonOption—52,5001.3—
David AndersonOption5,760—123.9—
David AndersonOption3,901—147.9—
David AndersonOption666—113.7—
David AndersonOption3,333—125.7—
David AndersonOption10,000—50.1—
David AndersonOption11,666—43.8—
David AndersonOption5,670—88.2—
Francisco Diaz-MitomaOption16,14652094.2—
Francisco Diaz-MitomaOption7,9225,41145.9—
Francisco Diaz-MitomaOption—2,50017.25—
Francisco Diaz-MitomaOption—52,5001.3—
Francisco Diaz-MitomaOption666—108.3—
Francisco Diaz-MitomaOption3,333—116.7—
Francisco Diaz-MitomaOption10,000—49.2—
Francisco Diaz-MitomaOption11,666—49.8—
Francisco Diaz-MitomaOption5,571—89.7—
Jeffrey BaxterOption32,2911,04194.5—
Jeffrey BaxterOption15,83710,82945.9—
Jeffrey BaxterOption—3,33317.25—
Jeffrey BaxterOption—70,0001.3—
Jeffrey BaxterOption13,069—123.9—
Jeffrey BaxterOption5,202—147.9—
Jeffrey BaxterOption666—113.7—
Jeffrey BaxterOption5,000—125.7—
Jeffrey BaxterOption15,000—50.1—
Jeffrey BaxterOption16,666—43.8—
Jeffrey BaxterOption14,173—88.2—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Steven GillisIndependent · Board Chair · Audit Committee · Compensation Committee · Nominating and Governance Committee (Chair)$103,750—$90,280—$0$194,028
Joanne CordeiroIndependent · Audit Committee · Compensation Committee (Chair)67,500—60,176—0127,676
Blaine H. McKeeIndependent · Audit Committee (Chair)60,000—60,176—0120,176
Michel De WildeIndependent · Compensation Committee47,500—60,176—0107,676
Damian BragaIndependent · Nominating and Governance Committee45,000—60,176—0105,176
Vaughn HimesIndependent · Nominating and Governance Committee33,750—54,401—088,151

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2023
Cash retainers and fees$357,500
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$357,500

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names VBI Vaccines Inc/BC as a peer

Companies that benchmark against VBIVQ

No companies currently name VBIVQ as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies VBI Vaccines Inc/BC names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Novavax, Inc.2025John Jacobs$792,917$3,545,435$3,763,292$640,331$8,856,015
2Dynavax Technologies Corporation2024Ryan Spencer835,0014,902,1501,824,299641,9078,210,775
3Akebia Therapeutics, Inc.2025John Butler864,0102,164,3382,024,798580,9735,652,339
4Emergent BioSolutions Inc.2025Joseph Papa1,037,3851,638,5001,191,5001,446,6405,321,147
5Rigel Pharmaceuticals, Inc.2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
6Heron Therapeutics, Inc.2025Craig Collard689,431946,2541,352,917517,1893,516,291
7Gritstone bio, Inc.2023Andrew Allen645,8332,429,8300355,2083,444,071
8C4 Therapeutics, Inc.2025Andrew Hirsch694,925710,730848,007573,3132,940,975
9Assembly Biosciences, Inc.2025Jason Okazaki647,500661,671573,574585,0002,482,987
10Sangamo Therapeutics, Inc.2024Alexander Macrae716,366909,4000825,2542,457,450
11Precision BioSciences, Inc.2025Michael Amoroso650,8751,025,086002,189,467
12Inovio Pharmaceuticals, Inc.2025Jacqueline Shea728,000346,101351,955144,1441,587,155
13Homology Medicines, Inc.2025Jodie Morrison645,600335,280220,792355,0801,558,870
14Chimerix, Inc.2023Mike Sherman514,695183,112778,51101,517,854
15Agenus Inc.2025Garo Armen715,2600141,00001,350,325
16VBI Vaccines Inc/BC2023Jeffrey Baxter697,9280121,7360893,546
—Adaptimmune Therapeutics plc.——————not in coverage universe
—Jounce Therapeutics, Inc.——————not in coverage universe
—Karyopharm Therapeutics Inc.——————not in coverage universe
—Vaxart Inc.——————not in coverage universe
—Vaxxinity, Inc.——————not in coverage universe
—Icosavax, Inc.——————not in coverage universe
—Axcella Health Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
VBI Vaccines Inc/BCnot disclosedOption 100not disclosednot disclosed
Adaptimmune Therapeutics plc.not disclosednot disclosednot disclosednot disclosed
Agenus Inc.125%Options 100not disclosedAon Radford
Akebia Therapeutics, Inc.90%Options 50 · RSU 25 · MSU 25NoPearl Meyer
Assembly Biosciences, Inc.not disclosednot disclosedNoAlpine Rewards, LLC
Axcella Health Inc.not disclosednot disclosednot disclosednot disclosed
C4 Therapeutics, Inc.120%not disclosednot disclosedPearl Meyer
Chimerix, Inc.85%Option 86 · RSU 14not disclosedAon
Dynavax Technologies Corporation102.5%Options 34 · RSU 33 · PSU 33Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology IndexAlpine
Emergent BioSolutions Inc.107%Options 50 · PSU 50NoWTW
Gritstone bio, Inc.100%RSU 100not disclosedAon
Heron Therapeutics, Inc.100%Option 66.67 · RSU 33.33not disclosedCompensia, Inc.
Homology Medicines, Inc.not disclosednot disclosednot disclosedAon plc
Icosavax, Inc.not disclosednot disclosednot disclosednot disclosed
Inovio Pharmaceuticals, Inc.33%not disclosedYes — Relative TSRAon (Human Capital Solutions practice)
Jounce Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Karyopharm Therapeutics Inc.not disclosednot disclosednot disclosednot disclosed
Novavax, Inc.95%Options 50 · RSU 50not disclosedPearl Meyer
Precision BioSciences, Inc.115%RSU 100not disclosedAon
Rigel Pharmaceuticals, Inc.124%Options 75 · RSU 25NoPearl Meyer
Sangamo Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Vaxart Inc.not disclosednot disclosednot disclosednot disclosed
Vaxxinity, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-25—————
20232023-06-232,262,957230,12840,77390.77%Passed
20222022-06-22—————
20212021-06-09—————
20202020-06-18123,630,41902,185,126100%Passed
20192019-06-13—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20242024-06-25—a
20232023-06-2390.77%b
20222022-06-22—c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “The affirmative vote of the holders of Common Shares having a majority of the votes cast by the holders of all Common Shares present or represented and voting on such matter will be required for approval, on an advisory basis, of the compensation of our Named Executive Officers (the "Named Executive Officers" or "NEOs") as set forth in the accompanying Proxy Statement.”.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

No insider equity transactions reported since the proxy statement.

Sources (31 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Jeffrey Baxter. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table for 2023 and 2022” · page 38. As printed: 893,546. View filing ↗
  • Section 01, David Anderson. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table for 2023 and 2022” · page 38. As printed: 564,555. View filing ↗
  • Section 01, Francisco Diaz-Mitoma. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table for 2023 and 2022” · page 38. As printed: 549,221. View filing ↗
  • Section 08, Steven Gillis. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 194,028. View filing ↗
  • Section 08, Joanne Cordeiro. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 127,676. View filing ↗
  • Section 08, Blaine H. McKee. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 120,176. View filing ↗
  • Section 08, Michel De Wilde. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 107,676. View filing ↗
  • Section 08, Damian Braga. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 105,176. View filing ↗
  • Section 08, Vaughn Himes. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 88,151. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 90.77% (votes for as printed: 2,262,957). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-06-23. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 357,500 + equity 0 + all other 0 = 357,500, summed across the director compensation table rows.
  • Novavax, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. View filing ↗
  • Dynavax Technologies Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. View filing ↗
  • Akebia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. View filing ↗
  • Emergent BioSolutions Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. View filing ↗
  • Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
  • Heron Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. View filing ↗
  • Gritstone bio, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Gritstone bio, Inc.'s own proxy. As printed: 3,444,071. View filing ↗
  • C4 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics, Inc.'s own proxy. As printed: 2,940,975. View filing ↗
  • Assembly Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Assembly Biosciences, Inc.'s own proxy. As printed: 2,482,987. View filing ↗
  • Sangamo Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in Sangamo Therapeutics, Inc.'s own proxy. As printed: 2,457,450. View filing ↗
  • Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
  • Inovio Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Inovio Pharmaceuticals, Inc.'s own proxy. As printed: 1,587,155. View filing ↗
  • Homology Medicines, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Homology Medicines, Inc.'s own proxy. As printed: 1,558,870. View filing ↗
  • Chimerix, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix, Inc.'s own proxy. As printed: 1,517,854. View filing ↗
  • Agenus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus Inc.'s own proxy. As printed: 1,350,325. View filing ↗
  • VBI Vaccines Inc/BC (subject), Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in VBI Vaccines Inc/BC's own proxy. As printed: 893,546. View filing ↗
  • Section 10a, Chimerix, Inc. reciprocity. DEF 14A. Chimerix, Inc. names VBI Vaccines Inc/BC in its own disclosed peer group (read from its most recent proxy). View filing ↗